A fish oil supplement called EPA-E reduced heart attack deaths from 56% to 29% in rats with high triglycerides, according to Gram Research analysis of a 2026 European Heart Journal study. The protection worked through multiple mechanisms beyond just lowering triglycerides, including reducing inflammation, cell death, and oxidative stress in heart tissue. However, these findings are from animal studies and require human clinical trials to confirm they apply to people.
A new study found that a specific type of fish oil called EPA-E may help hearts recover better after a heart attack, even beyond just lowering triglycerides (a type of fat in the blood). Researchers gave rats with high triglycerides either EPA-E supplements or a placebo for two weeks, then induced heart attacks. The rats that received EPA-E had smaller heart damage, lower death rates, and better heart function compared to those without the supplement. The protection appeared to work through multiple pathways in the heart, reducing inflammation, cell damage, and stress. This suggests EPA-E could offer heart protection that goes deeper than previously understood.
Key Statistics
A 2026 animal study published in the European Heart Journal found that EPA-E supplementation reduced heart attack mortality from 56% to 29% in rats with high triglycerides, while also reducing infarct size compared to untreated animals.
According to research reviewed by Gram, EPA-E treatment reduced multiple harmful processes in damaged heart tissue including apoptosis (cell death), fibrosis (scarring), oxidative stress, and inflammatory cell recruitment in a 63-rat study.
The 2026 study found no correlation between triglyceride reduction and heart protection, suggesting EPA-E’s cardioprotective effects work through mechanisms beyond its triglyceride-lowering properties.
The Quick Take
- What they studied: Whether a fish oil supplement called EPA-E (eicosapentaenoic acid ethyl ester) can protect the heart during and after a heart attack, and how it works beyond just lowering triglycerides
- Who participated: 63 male rats divided into three groups: those with high triglycerides receiving EPA-E (21 rats), those with high triglycerides receiving placebo (27 rats), and a healthy control group (15 rats)
- Key finding: Rats receiving EPA-E had 29% mortality after heart attack compared to 56% in untreated high-triglyceride rats, with significantly smaller areas of heart damage (P < 0.05)
- What it means for you: This research suggests EPA-E supplements may offer heart protection beyond triglyceride reduction, though human studies are needed to confirm these findings apply to people
The Research Details
This was an animal study using rats to test how EPA-E affects the heart during a heart attack. Researchers first created high triglyceride levels in rats by feeding them a high-sugar diet. They then gave some rats EPA-E supplements and others a placebo for two weeks. After this preparation period, the researchers deliberately caused a heart attack in all the rats by temporarily blocking blood flow to the heart. Twenty-four hours later, they examined the hearts to measure damage and studied the chemical changes that occurred.
The researchers used multiple advanced techniques to understand what was happening inside the heart tissue. They measured heart function using ultrasound, looked at the size of damaged areas, and analyzed the chemical signatures of the heart tissue to understand the protective mechanisms at work.
This type of study is important because it allows researchers to control variables precisely and examine heart tissue directly, which cannot be done in humans. However, results in rats don’t always translate directly to humans, so these findings need confirmation in human studies.
Understanding how EPA-E protects the heart at a molecular level is crucial because it could lead to better treatments for heart attack patients. If the protection works through multiple pathways rather than just lowering triglycerides, it might help patients who don’t respond well to triglyceride-lowering drugs alone. This research provides a foundation for developing more targeted therapies.
This study was published in the European Heart Journal, a highly respected medical journal. The researchers used multiple measurement techniques to confirm their findings, which strengthens confidence in the results. However, this is an animal study, so results may not directly apply to humans. The sample size was moderate (63 rats total), and the study was relatively short-term (2 weeks of treatment plus 24 hours of observation after heart attack). Human clinical trials would be needed to confirm these protective effects in people.
What the Results Show
Rats treated with EPA-E showed significantly better outcomes after heart attack compared to untreated rats with high triglycerides. The death rate was 29% in EPA-E-treated rats versus 56% in untreated rats, representing a substantial difference in survival. The size of the heart damage was also smaller in EPA-E-treated animals compared to both the untreated high-triglyceride group and the healthy control group.
Interestingly, the protective effect of EPA-E was not directly related to how much it lowered triglycerides. Even though EPA-E reduced circulating triglycerides, the amount of triglyceride reduction didn’t predict how much heart protection occurred. This suggests EPA-E works through additional mechanisms beyond simple triglyceride reduction.
The researchers discovered that EPA-E reduced multiple harmful processes in the damaged heart tissue. These included reduced cell death (apoptosis), less scarring (fibrosis), lower oxidative stress (cellular damage from reactive molecules), and decreased inflammatory cell recruitment. The supplement also improved how well the heart’s energy-producing structures (mitochondria) functioned after the heart attack.
EPA-E treatment improved the heart’s metabolic and lipid profiles both in the bloodstream and within the heart tissue itself. The supplement promoted a ‘pro-resolving’ response, meaning it helped the body’s natural healing processes work more effectively. All rats showed similar decreases in overall heart function immediately after the heart attack, suggesting EPA-E’s main benefit is in protecting tissue and improving survival rather than preventing the initial functional decline.
Previous research has shown that EPA and other omega-3 fatty acids can lower triglycerides and reduce heart disease risk. This study builds on that knowledge by showing that EPA-E offers direct protection to heart tissue through multiple mechanisms beyond triglyceride reduction. The finding that triglyceride reduction alone doesn’t explain the protective effect is novel and suggests EPA-E has additional beneficial properties that weren’t previously appreciated.
This study used only male rats, so results may not apply equally to females. The study was short-term, examining only the first 24 hours after heart attack, so long-term effects are unknown. Animal studies don’t always translate to humans due to differences in metabolism and physiology. The study didn’t test different doses of EPA-E, so the optimal dose for humans remains unclear. Additionally, this was a single study, so results need confirmation by other research groups before strong conclusions can be drawn.
The Bottom Line
Based on this research, EPA-E supplementation shows promise for heart protection in the context of high triglycerides, but human clinical trials are needed before recommending it as a standard treatment. Current evidence supports the use of EPA-E in patients with elevated triglycerides as part of a comprehensive heart disease prevention strategy, though the specific heart-protective benefits shown in this animal study require human confirmation. Confidence level: Moderate (animal study with promising results, but human evidence needed).
People with high triglycerides, those with a history of heart disease, and individuals at high risk for heart attacks should be aware of this research. However, anyone considering EPA-E supplementation should discuss it with their doctor first, as this study was conducted in animals and hasn’t yet been confirmed in humans. People taking blood-thinning medications should be especially cautious, as omega-3 supplements can have mild blood-thinning effects.
In this animal study, EPA-E was given for only two weeks before the heart attack occurred. It’s unknown how long humans would need to take EPA-E before experiencing similar protective benefits, or whether the protection would persist long-term. Human studies would be needed to establish realistic timelines for seeing benefits.
Frequently Asked Questions
Does fish oil help protect your heart after a heart attack?
A 2026 animal study found that EPA-E (a fish oil derivative) reduced heart attack deaths from 56% to 29% in rats with high triglycerides and reduced the size of heart damage. However, human studies are needed to confirm these protective effects apply to people.
How does EPA-E protect the heart beyond lowering triglycerides?
Research shows EPA-E reduces inflammation, cell death, scarring, and oxidative stress in heart tissue while improving how mitochondria function. These protective mechanisms appear independent of triglyceride reduction, suggesting multiple pathways of benefit.
What is the difference between EPA and EPA-E supplements?
EPA-E (eicosapentaenoic acid ethyl ester) is a modified form of EPA designed for better absorption and stability. This study specifically tested EPA-E, so it’s unclear whether regular EPA supplements would provide identical benefits.
Can I take EPA-E supplements to prevent a heart attack?
While this animal study shows promise, human clinical trials are needed before EPA-E can be recommended for heart attack prevention. Discuss with your doctor whether EPA-E supplementation is appropriate for your individual risk factors and medications.
How long do you need to take EPA-E before it protects your heart?
This animal study used only two weeks of EPA-E treatment before testing heart protection. The timeline for human benefit is unknown and would require clinical trials to establish. Your doctor can advise on appropriate duration based on your health status.
Want to Apply This Research?
- Track daily EPA-E supplementation intake (dose in grams) and monthly triglyceride levels if available from blood tests, correlating changes with cardiovascular symptoms or exercise tolerance
- Users could set a daily reminder to take EPA-E supplements at the same time each day, combined with logging their triglyceride-lowering diet choices (reduced sugar intake) to reinforce the lifestyle changes that work synergistically with supplementation
- Establish a baseline triglyceride level, then monitor changes every 3 months through blood work while tracking EPA-E adherence. Note any changes in exercise tolerance, shortness of breath, or other cardiac symptoms to identify patterns
This research was conducted in animals (rats) and has not yet been confirmed in human studies. EPA-E supplementation should not be used as a substitute for proven heart attack treatments or prevention strategies. Anyone considering EPA-E supplements, especially those with existing heart disease, taking blood-thinning medications, or at high risk for bleeding, should consult with their healthcare provider before starting supplementation. Results from animal studies do not always translate to humans, and individual responses to supplements vary. This article is for educational purposes and should not be interpreted as medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.